StreetAlpha.app
Home › Stocks › VIR

Vir Biotechnology, Inc. (VIR)

Healthcare
$8.39
▼ −5.41%
LAST CLOSE · NOV 20

Vir Biotechnology develops product candidates for serious infectious diseases and cancer. It last closed at $8.39 on Nov 20, down 5.41% on the day. The next earnings report for VIR is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, VIR reported EPS of -$0.57. Over its last 8 reports the stock moved an average of 9.0% the session after earnings. Over the last 12 months VIR insiders bought $0 of stock on the open market and sold $8.2M, according to SEC Form 4 filings.

AI Auto Pilots
Is VIR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold VIR.

Key Stats

Last 12 months
Results
Revenue
$302.8M
+1696.0% vs a year ago
Net income
−$184.8M
−61.0% margin
EPS (diluted)
−$1.18
Free cash flow
−$141.8M
−46.8% margin
Valuation
Market cap
$1.4B
171.3M shares
P/E
–
No P/E while losing money
Price to sales
4.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$218.9M
At Sep 30
Shareholder equity
$896.0M
Shares outstanding
171.3M
At Oct 28
CEOGeorge Scangos
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.1B$1.1BFY2021FY2022: $1.6B$1.6BFY2022FY2023: $86.2M$86.2MFY2023FY2024: $74.2M$74.2MFY2024FY2025: $68.6M$68.6MFY2025

From VIR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
-$0.57
Quarter ended Sep 2026
Year ago EPS
-$1.17
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.76Dec '24Mar 2025: -$0.88Mar '25Jun 2025: -$0.80Jun '25Sep 2025: -$1.17Sep '25Dec 2025: -$0.30Dec '25Mar 2026: -$0.85Mar '26Jun 2026: $0.47Jun '26Sep 2026: -$0.57Sep '26Latest -$0.57
Revenue by quarter
Dec 2024: $12.4MDec '24Mar 2025: $3.0MMar '25Jun 2025: $1.2MJun '25Sep 2025: $240,000Sep '25Dec 2025: $64.1MDec '25Jun 2026: $238.9MJun '26Latest $238.9M
How VIR moved after its last 8 reports
Average move the session after a report ±9.0%
Nov 4, 2026After the close−6.4%
Aug 5, 2026After the close−3.8%
May 6, 2026After the close−9.9%
Feb 23, 2026After the close+27.7%
Jan 12, 2026Time not announced+1.2%
Nov 5, 2025After the close−5.2%
Aug 6, 2025After the close−14.4%
May 7, 2025After the close−3.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on VIRStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on VIR
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on VIR

Technical Analysis

VIR · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, oversold

The stock is 32% below its 20 day and 31% below its 50 day average. It is 17% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), oversold. The nearest support is the Pivot S1 at $8.18, and the nearest resistance the Pivot at $8.55.

Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityHigh, 9.5%/day
Key levels
$14.3852 week high+71.4%
$11.1020 day average+32.3%
$10.9650 day average+30.6%
$10.38100 day average+23.7%
$9.80200 day average+16.8%
$9.70Swing high (Aug 6)+15.6%
$8.76Pivot R1+4.4%
$8.55Pivot+1.9%
$8.39Last close
$8.18Pivot S1−2.5%
$8.16Swing low (Jun 10)−2.7%
$5.4552 week low−35.0%
Indicators
RSI (14)32.90Weak, oversold below 30Neutral
MACD-0.52Below its signal lineBearish
Stochastic1.1Near the bottom of its rangeOversold
ADX (14)23.9Weak trend
Williams %R-99.2Oversold below −80, overbought above −20Oversold
CCI (20)-155.2Oversold below −100, overbought above 100Oversold
Rate of change−31.3%Change over 10 sessionsBearish
ATR (14)$0.80Typical daily range, 9.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for VIR

What happened before

See how VIR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow VIR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How VIR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for VIRHow many large options trades hit VIR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

VIR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲138 buying vs 107 selling
  • ▼Held by funds -3.5 pts
  • ▲Funds holding +29
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding266237+12.2%
In funds' top 1056−16.7%
Held by funds82.1%85.6%−3.5 pts
New / increased53 / 8531 / 92+12.2%
Reduced / sold out84 / 2377 / 43−10.8%
Put/call ratio6.180.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VIR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

VIR Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$8.2M26 sales · 9 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $1.3M2026-01 sold $130K2026-02 sold $1.2M2026-03 sold $279K2026-04 sold $864K2026-05 sold $221K2026-06 sold $34K2026-11 sold $42KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 3Verneuil Vanina deEVP, General Counsel, Corp SecSale plan3,750$11.18$42K
Jun 1Brent SabatiniSVP, Chief Accounting OfficerSale plan379$9.45$4K
Jun 1Janet NapolitanoDirectorSale plan3,200$9.45$30K
May 1Vicki L SatoDirectorSale plan22,000$10.05$221K
Apr 6Backer Marianne DePresident and CEOSale plan72,559$9.16$664K
Apr 1Vicki L SatoDirectorSale plan22,000$9.07$200K
Every insider buy and sale for VIR over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See VIR insider trades →

From SEC Form 4 filings by VIR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VIR is in one of them and how their past VIR trades turned out.

VIR in the AI portfolios
Loading…

VIR News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VIR in an article yet. Here's the latest on the wider market.

VIR in the news

About Vir Biotechnology

Vir Biotechnology is a biotechnology company based in San Francisco, California. It is developing product candidates, none yet approved, for serious infectious diseases and cancer, built on several technology platforms. The company also works with other drugmakers through collaboration and licensing agreements, both acquiring rights to some candidates and granting rights to others for further development.

Headquarters
San Francisco, CA
Founded
2016